254 related articles for article (PubMed ID: 30530905)
1. The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution.
Zhao L; Zhu C; Lu M; Chen C; Nie X; Abudukerimu B; Zhang K; Ning Z; Chen Y; Cheng J; Xia F; Wang N; Jensen MD; Lu Y
J Endocrinol; 2019 Feb; 240(2):271-286. PubMed ID: 30530905
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide treatment counteracts alterations in adipose tissue metabolism induced by orchiectomy in rats.
Model JFA; Lima MV; Ohlweiler R; Sarapio E; Vogt ÉL; Rocha DS; de Souza SK; Vinagre AS
Life Sci; 2021 Aug; 278():119586. PubMed ID: 33957171
[TBL] [Abstract][Full Text] [Related]
3. Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.
Decara J; Rivera P; Arrabal S; Vargas A; Serrano A; Pavón FJ; Dieguez C; Nogueiras R; Rodríguez de Fonseca F; Suárez J
Acta Physiol (Oxf); 2018 Apr; 222(4):e13008. PubMed ID: 29193738
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning.
Wang J; Zhou Y; Long D; Wu Y; Liu F
Biochem Biophys Res Commun; 2023 Jul; 664():142-151. PubMed ID: 37167707
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.
Zhao L; Li W; Zhang P; Wang D; Yang L; Yuan G
Endocrine; 2024 Feb; ():. PubMed ID: 38378894
[TBL] [Abstract][Full Text] [Related]
6. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.
Decara J; Arrabal S; Beiroa D; Rivera P; Vargas A; Serrano A; Pavón FJ; Ballesteros J; Dieguez C; Nogueiras R; Rodríguez de Fonseca F; Suárez J
Biofactors; 2016 Nov; 42(6):600-611. PubMed ID: 27213962
[TBL] [Abstract][Full Text] [Related]
7. Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice.
Zhang N; Liu C; Zhang Y; Xu D; Gui L; Lu Y; Zhang Q
Biochem Biophys Res Commun; 2021 Apr; 548():120-126. PubMed ID: 33640604
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
Zhu E; Yang Y; Zhang J; Li Y; Li C; Chen L; Sun B
Oncotarget; 2016 Dec; 7(49):81077-81089. PubMed ID: 27835589
[TBL] [Abstract][Full Text] [Related]
9. [Electroacupuncture improves obesity and promotes white adipose tissue browning by regulating central glucagon-like peptide-1].
Zhu Y; Tian J; Shao YW; Zhao J; Jia SH; Shu Q
Zhen Ci Yan Jiu; 2023 Aug; 48(8):727-35. PubMed ID: 37614130
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats.
Model JFA; Lima MV; Ohlweiler R; Lopes Vogt É; Rocha DS; Souza SK; Türck P; Araújo ASDR; Vinagre AS
Mol Cell Endocrinol; 2021 Mar; 524():111158. PubMed ID: 33444670
[TBL] [Abstract][Full Text] [Related]
11. Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue.
Tavares G; Rosendo-Silva D; Simões F; Eickhoff H; Marques D; Sacramento JF; Capucho AM; Seiça R; Conde SV; Matafome P
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768789
[TBL] [Abstract][Full Text] [Related]
12. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.
Namekawa J; Nemoto S; Sunada G; Takanashi Y; Fujio S; Shirai M; Asai F
J Vet Med Sci; 2018 Oct; 80(10):1515-1523. PubMed ID: 30175725
[TBL] [Abstract][Full Text] [Related]
14. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
Kaineder K; Birngruber T; Rauter G; Obermüller B; Eichler J; Münzker J; Al-Zoughbi W; Mautner SI; Torekov SS; Hartmann B; Kotzbeck P; Pieber TR
Int J Obes (Lond); 2017 Aug; 41(8):1263-1270. PubMed ID: 28507313
[TBL] [Abstract][Full Text] [Related]
15. Chronic Rapamycin Treatment Improved Metabolic Phenotype but Inhibited Adipose Tissue Browning in High-Fat Diet-Fed C57BL/6J Mice.
Wang Y; He Z; Li X
Biol Pharm Bull; 2017; 40(9):1352-1360. PubMed ID: 28867720
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.
Oliveira FCB; Bauer EJ; Ribeiro CM; Pereira SA; Beserra BTS; Wajner SM; Maia AL; Neves FAR; Coelho MS; Amato AA
Front Endocrinol (Lausanne); 2021; 12():803363. PubMed ID: 35069450
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1.
Xu F; Lin B; Zheng X; Chen Z; Cao H; Xu H; Liang H; Weng J
Diabetologia; 2016 May; 59(5):1059-69. PubMed ID: 26924394
[TBL] [Abstract][Full Text] [Related]
18. Depot-Specific Changes in Fat Metabolism with Aging in a Type 2 Diabetic Animal Model.
Park SE; Park CY; Choi JM; Chang E; Rhee EJ; Lee WY; Oh KW; Park SW; Kang ES; Lee HC; Cha BS
PLoS One; 2016; 11(2):e0148141. PubMed ID: 26894429
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
Lu N; Sun H; Yu J; Wang X; Liu D; Zhao L; Sun L; Zhao H; Tao B; Liu J
PLoS One; 2015; 10(7):e0132744. PubMed ID: 26177280
[TBL] [Abstract][Full Text] [Related]
20. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass.
Girousse A; Tavernier G; Valle C; Moro C; Mejhert N; Dinel AL; Houssier M; Roussel B; Besse-Patin A; Combes M; Mir L; Monbrun L; Bézaire V; Prunet-Marcassus B; Waget A; Vila I; Caspar-Bauguil S; Louche K; Marques MA; Mairal A; Renoud ML; Galitzky J; Holm C; Mouisel E; Thalamas C; Viguerie N; Sulpice T; Burcelin R; Arner P; Langin D
PLoS Biol; 2013; 11(2):e1001485. PubMed ID: 23431266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
